Cortexyme, Inc. (CRTX): Price and Financial Metrics

Cortexyme, Inc. (CRTX): $6.24

-2.82 (-31.13%)

POWR Rating

Component Grades













Add CRTX to Watchlist
Sign Up

Industry: Biotech


of 453

in industry

CRTX Stock Price Chart Interactive Chart >

Price chart for CRTX

CRTX Price/Volume Stats

Current price $6.24 52-week high $121.98
Prev. close $9.06 52-week low $5.60
Day low $5.60 Volume 2,504,972
Day high $6.64 Avg. volume 820,173
50-day MA $12.12 Dividend yield N/A
200-day MA $47.94 Market Cap 186.44M

Cortexyme, Inc. (CRTX) Company Bio

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases.

CRTX Latest News Stream

Event/Time News Detail
Loading, please wait...

CRTX Latest Social Stream

Loading social stream, please wait...

View Full CRTX Social Stream

Latest CRTX News From Around the Web

Below are the latest news stories about Cortexyme Inc that investors may wish to consider to help them evaluate CRTX as an investment opportunity.

Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Ab...

Benzinga | January 17, 2022

Why Cortexyme Stock Imploded in 2021

The clinical-stage drugmaker's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study. Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. Since announcing these disappointing trial results late last year, Cortexyme has said that it plans to trial the drug yet again.

Yahoo | January 12, 2022

3 Most-Shorted Stocks at 52-Week Lows to Buy

In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors.

Chris Tyler on InvestorPlace | January 7, 2022

Do Institutions Own Cortexyme, Inc. (NASDAQ:CRTX) Shares?

If you want to know who really controls Cortexyme, Inc. ( NASDAQ:CRTX ), then you'll have to look at the makeup of its...

Yahoo | January 4, 2022

Wall Streets Take On Cortexyme Inc. (NASDAQ: CRTX) Stock.

Cortexyme Inc. (NASDAQ:CRTX) traded at $12.81 at close of the session on Tuesday, 12/21/21, made an upward move of 2.81% on its previous days price. Looking at the stock we see that its previous close was $12.46 and the beta (5Y monthly) reads 0.75 with the days price range being $12.19 $13.179. In terms Wall Streets Take On Cortexyme Inc. (NASDAQ: CRTX) Stock. Read More »

Stocks Register | December 22, 2021

Read More 'CRTX' Stories Here

CRTX Price Returns

1-mo -50.12%
3-mo -56.24%
6-mo -88.96%
1-year -83.30%
3-year N/A
5-year N/A
YTD -50.55%
2021 -54.57%
2020 -50.52%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7274 seconds.